TACE–TARE Therapy: Innovative Minimally Invasive Cancer Treatments

TACE–TARE therapy represents one of the most important advancements in modern interventional oncology, offering highly targeted, minimally invasive treatment options for patients with primary liver cancer, metastatic liver tumors, and other localized malignancies. These two techniques—Transarterial Chemoembolization (TACE) and Transarterial Radioembolization (TARE)—deliver cancer-killing agents directly to the tumor through its arterial blood supply. By bypassing the systemic circulation, they allow higher, more effective doses at the tumor site while preserving surrounding healthy tissues.

As liver tumors receive the majority of their blood supply from the hepatic artery, these therapies exploit this vascular anatomy to achieve maximal tumor destruction with minimal systemic toxicity. Both procedures are performed by interventional radiologists using advanced imaging guidance, typically as part of a multidisciplinary treatment plan combining oncology, hepatology, and surgical expertise.

This article provides an in-depth, clinically accurate overview of how TACE and TARE work, who benefits from them, procedural processes, risks, benefits, and expected outcomes—written in clear, high-quality English and suitable for publication under a medical institution like MedicalPoint Hospital.

What Is TACE–TARE?

TACE–TARE refers to two interventional procedures used to treat liver cancer and other tumors that cannot be removed surgically or have not responded to systemic treatments.

TACE – Transarterial Chemoembolization

TACE combines localized chemotherapy with arterial embolization. Chemotherapy drugs are delivered directly into the blood vessel feeding the tumor, followed by embolic particles that block blood flow. This achieves:

• Ischemia (starves the tumor of oxygen and nutrients)

• Sustained chemotherapy exposure (drugs remain trapped inside the tumor)

TARE – Transarterial Radioembolization (Selective Internal Radiation Therapy – SIRT)

TARE uses microscopic radioactive beads, typically containing Yttrium-90, which emit targeted radiation once lodged in the tumor’s microvasculature. This internal radiation destroys cancer cells gradually over weeks with high precision.

Both treatments rely on catheter-based techniques and advanced imaging guidance. They are considered standard-of-care options for many patients with hepatocellular carcinoma (HCC) and metastatic liver disease.

How Do TACE and TARE Work?

1. Catheter-Based Access

Both procedures begin with the insertion of a catheter into a peripheral artery:

• usually the femoral artery (groin)

• or the radial artery (wrist)

Using fluoroscopy (X-ray imaging), the interventional radiologist navigates the catheter through the vascular system until it reaches the hepatic artery branches supplying the tumor.

2. Precision Targeting

Angiography is performed to map the tumor’s exact blood supply and to avoid non-target organs (e.g., stomach, pancreas). Once the feeding artery is clearly identified, the treatment is delivered.

TACE: Targeted Chemotherapy with Embolization

TACE involves a two-step therapeutic approach:

a. Local Chemotherapy Delivery

Drugs commonly used include:

• Doxorubicin

• Cisplatin

• Epirubicin

• Mitomycin C

These are mixed with an oily contrast agent (e.g., Lipiodol) to increase retention inside the tumor.

b. Embolization Phase

After chemotherapy is injected, small embolic particles block the vessel, achieving:

• Longer drug contact with tumor tissue

• Reduced blood flow, intensifying tumor cell death

• Minimal systemic side effects due to limited bloodstream exposure

This combination enhances tumor shrinkage and allows repeated sessions if the disease remains locally controlled.

TARE: Precision Internal Radiation Therapy

TARE uses Y-90 radioactive microspheres that deliver direct radiation over 1–2 weeks.

Key therapeutic advantages:

• Radiation travels only a few millimeters, sparing healthy liver parenchyma

• Effective even when portal vein thrombosis is present (conditions where TACE is contraindicated)

• Suitable for tumors not responsive to chemotherapy

• Can be used as a bridge to liver transplantation

After administration, radiation gradually decreases while microspheres remain permanently embedded within the tumor, continuing therapeutic action.

Advantages of TACE and TARE

Compared to systemic chemotherapy or open surgery, these techniques offer multiple benefits:

Minimally invasive

Only a small puncture is required—no large incisions.

Highly targeted therapy

Agents are delivered directly to the tumor, not the entire body.

Lower systemic toxicity

Few whole-body chemotherapy or radiation side effects.

Shorter hospital stay

Most patients are discharged within 24–48 hours.

Repeatable if necessary

Multiple sessions can be performed for progressive or recurrent disease.

Improved survival

Studies from The Lancet Oncology and Journal of Hepatology show improved progression-free survival and prolonged overall survival in selected patients.

Enhances quality of life

Reduces tumor burden, controls symptoms, and maintains liver function.

Which Conditions Can Be Treated with TACE and TARE?

Primary Liver Cancer

• Hepatocellular carcinoma (HCC) – the most common indication

• Intrahepatic cholangiocarcinoma

Metastatic Liver Disease

Effective for metastases from:

• Colorectal cancer

• Breast cancer

• Pancreatic tumors

• Melanoma

• Neuroendocrine tumors (NETs)

Other Selected Tumors

In rare cases, TACE/TARE can also be used for:

• Renal cell carcinoma metastases

• Lung cancer metastases

• Sarcomas

• Adrenal tumors

These procedures are especially beneficial for unresectable tumors or when the patient cannot tolerate surgery due to advanced disease or poor liver function.

Who Is a Candidate for TACE–TARE Therapy?

Ideal candidates typically include patients who:

• Have inoperable liver tumors

• Have limited extrahepatic disease

• Maintain adequate liver function (Child-Pugh A or B)

• Are not candidates for curative surgery or transplantation

• Require bridging or downstaging before liver transplant

TARE is particularly suitable for patients with portal vein thrombosis, while TACE is often preferred for intermediate-stage HCC according to the Barcelona Clinic Liver Cancer (BCLC) classification.

What to Expect Before, During, and After TACE or TARE

Before the Procedure

Patients undergo a detailed assessment including:

• Blood tests (liver enzymes, coagulation, kidney function)

• CT or MRI of the liver

• Pre-procedural angiography

• Lung shunt evaluation (for TARE)

Patients may also need:

• Fasting for 6–8 hours

• Temporary adjustment or discontinuation of blood-thinning medications

During the Procedure

• Performed under local anesthesia with sedation

• Catheter insertion takes place in an angiography suite

• Treatment delivery lasts 1–3 hours depending on complexity

• Patients remain comfortable and awake

After the Procedure

Most patients are monitored for several hours or overnight.

Common expected symptoms:

• Mild abdominal discomfort

• Low-grade fever

• Fatigue

• Nausea

These symptoms are known as post-embolization syndrome and usually resolve within a few days.

Follow-Up

A follow-up CT or MRI is performed after 4–6 weeks to evaluate treatment response. Additional sessions may be recommended depending on tumor status.

Risks and Potential Complications

Although TACE and TARE are safe when performed by experienced specialists, potential risks include:

Common but mild

• Fatigue

• Low fever

• Temporary liver enzyme elevation

• Nausea or mild abdominal pain

Less common but more serious

• Infection

• Bleeding at the catheter site

• Non-target embolization (rare but possible)

• Radiation-induced liver disease (TARE only, very rare)

• Worsening of liver function

Risk is minimized through careful pre-procedure imaging, liver function assessment, and precise catheter placement.

Conclusion

TACE and TARE therapies represent a major breakthrough in the treatment of liver cancer and other localized malignancies. These procedures deliver chemotherapy or internal radiation directly to the tumor, maximizing therapeutic effectiveness while minimizing side effects and preserving quality of life.

Their minimally invasive nature, precision targeting, and strong evidence base make them essential tools in interventional oncology—especially for patients who are not candidates for surgery, transplantation, or systemic chemotherapy.

At MedicalPoint Hospital, our interventional radiology and oncology teams work collaboratively to design personalized, evidence-based TACE–TARE treatment plans. With advanced imaging technology and expert clinical protocols, we deliver safe, effective, and modern cancer care tailored to each patient’s unique condition.

Patients with liver cancer or metastatic disease are encouraged to consult our specialists to determine whether TACE or TARE could provide a meaningful therapeutic benefit.